NCT00044720已完成4 期
An Open-label, Concentration Controlled, Randomized, 12 Month Study of Prograf + Rapamune + Cor
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 484 人开始时间: 2002年9月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 484
研究概览
简要总结
The incidence of efficacy failure at 12 months between two regimens.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 13 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 13 years or older, 40 kgs or more
- •End-stage renal disease
- •African-American/Black transplant recipient and/or repeat renal transplant recipient who lost a previous allograft
排除标准
- •Evidence of active infection
- •Evidence abnormal chest x-ray
- •Patients with HIV.
研究者
相似试验
已完成
2 期
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing SteroidsAsthmaNCT01479621Teva Branded Pharmaceutical Products R&D, Inc.909
已完成
2 期
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult PatientsTuberculosisTuberculosis, PulmonaryTuberculosis, Multidrug-ResistantTuberculosis, MDRDrug-Resistant TuberculosisNCT03338621Global Alliance for TB Drug Development455
进行中（未招募）
1 期
Study to evaluate the effectiveness of fluticasone furoate/vilanterol delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with existing COPD maintenance therapy alone in subjects with Chronic Obstructive Pulmonary Disease.EUCTR2011-002452-13-GBGlaxoSmithKline Research & Development Ltd3,161
进行中（未招募）
1 期
Study to evaluate the effectiveness of fluticasone furoate/vilanterol delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with existing Asthma maintenace therapy alone in subjects with Asthma.AsthmaEUCTR2011-005553-31-GBGlaxoSmithKline Research & Development Ltd4,233
终止
2 期
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term ExtensionLiver Transplant RejectionNCT03781414Novartis Pharmaceuticals129